> In early 1994, however, Green
Cross ceased manufacturing Fluosol due to lack
of interest from physicians and poor sales in their
angioplasty indication (Table 25.1). Improvements
in PTCA technology, notably the introduction of
specialized autoperfusion catheters, made the
need for Fluosol redundant.
OhYouRye t1_iveof51 wrote
Reply to comment by sonoma95436 in Lab-grown blood given to people in world-first clinical trial by filosoful
> In early 1994, however, Green Cross ceased manufacturing Fluosol due to lack of interest from physicians and poor sales in their angioplasty indication (Table 25.1). Improvements in PTCA technology, notably the introduction of specialized autoperfusion catheters, made the need for Fluosol redundant.